Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viaskin Peanut Long-term Follow-up Study (OLFUS-VIPES)
NCT01955109Phase 2Completed
- Sponsor
- DBV Technologies
- Start
- Sep 2013
- Primary completion
- Sep 2016
- Modality
- Transdermal Patches
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of peanut protein in peanut allergy, sponsored by DBV Technologies. Primary endpoint: Percentage of Treatment Responders at 24 months. Started Sep 2013; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT01955109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01955109.